Eisai's Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson's Disease
This article was originally published in PharmAsia News
Executive Summary
Eisai has pushed back the filing of its novel AMPA receptor antagonist perampanel for Parkinson's disease from fiscal 2007 to fiscal fourth quarter 2008 (ended March 31, 2009) in the U.S. and Europe because the drug failed to show an efficacy benefit over placebo in a Phase III study, Eisai said Oct. 30
You may also be interested in...
Eisai Drops Perampanel In Parkinson’s, Plans First Neuropathy Submission For 2010
Eisai announced April 11 it has abandoned development of its novel AMPA receptor antagonist perampanel in Parkinson's disease after a second Phase III trial failed, but the Tokyo firm is forging ahead with the compound in other neurological indications
Eisai Drops Perampanel In Parkinson’s, Plans First Neuropathy Submission For 2010
Eisai announced April 11 it has abandoned development of its novel AMPA receptor antagonist perampanel in Parkinson's disease after a second Phase III trial failed, but the Tokyo firm is forging ahead with the compound in other neurological indications
Eisai’s 2008 Eribulin NDA Plan Foiled; Beat To The Punch By BMS Drug
U.S. FDA has dealt a setback to Eisai's burgeoning oncology pipeline by denying the company's efforts to seek accelerated approval for its microtubule growth suppressor E7389 (eribulin mesylate)